NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Deutsche Bank 40th Annual Health Care May 7, 2015 at 10:00 a.m. ET.
Author: Business Wire
Clearside Biomedical, Inc. and Santen, Inc. Announce Research Collaboration in Glaucoma
ALPHARETTA, Ga. & EMERYVILLE, Calif.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies to treat eye diseases, and Santen Inc., a Santen Pharmaceuticals Co. subsidiary, will expand their research collaboration to include glaucoma.
Acucela Shareholders Elect New Board Members
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that shareholders have elected four new members to the Company’s Board of Directors (the “Board”) at today’s special meeting of the Company’s shareholders (the “Special Meeting”). At the Special Meeting,
Ocular Therapeutix to Present Eight Posters Highlighting its Sustained Release Hydrogel Platform Technology at the Association for Research in Vision and Ophthalmology Annual Meeting
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced new data will be presented on the company’s sustained release technology at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting at the Colorado Convention Center in Denver, Colorado, from May 3-7, 2015. The data presented will focus on the
pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida Announces May 8 for Third Quarter Fiscal Year 2015 Financial Results and Release Date and Conference Call Information
Second Sight Announces Senior Management Appointments in Commercialization and Manufacturing
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to restore functional vision to blind patients, today announced two senior management appointments in commercialization and manufacturing. As discussed on its fourth quarter 2014 conference call, the Company will be making several key hires as it continues the transition from an R&D focused organization
Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells in Asian Patients
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in Asian patients who were treated with Ocata’s proprietary RPE cells, manufactured using its DeltaCell™ Technology. These new data support previously reported positive long-term safety and signs of visual improvement, as presented in The Lancet of October 1
AqueSys XEN Gel Stent Data Supporting Safety and Effectiveness Presented at the American Society of Cataract & Refractive Surgery Annual Meeting
ALISO VIEJO, Calif.–(BUSINESS WIRE)–AqueSys XEN Gel Stent data supporting safety and effectiveness presented at the recent American Society of Cataract & Refractive Surgery annual meeting.
2015 Q1 Life Sciences Hiring Index Surges to All-Time High
WEST ORANGE, N.J.–(BUSINESS WIRE)–ZRG Partners, Inc. has announced the findings for its first quarter Global Life Sciences Hiring Index from 2015.
Clearside Biomedical, Inc. to Report Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide at 2015 ARVO Meeting
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies to treat eye diseases, will present its Phase 1/2 clinical trial results May 5 at the Association for Research and Vision in Ophthalmology meeting.
Eleven Biotherapeutics Reports First Quarter 2015 Financial Results
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics Reports First Quarter 2015 Financial Results
Magellan Health Reports First Quarter 2015 Financial Results Updates Guidance
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Magellan Health, Inc. (NASDAQ: MGLN) today reported financial results for the first quarter of 2015, as summarized below.
Monroe Capital Expands Credit Facility to Luxury Optical Holdings
CHICAGO–(BUSINESS WIRE)–Monroe Capital LLC today announced an increase in the credit facility to Luxury Optical Holdings (“LOH”) to support continued growth of the business. LOH is a portfolio company of aPriori Capital Partners and Goode Partners. Based in Las Vegas, Nevada, Luxury Optical Holdings is the leading retailer of luxury eyewear with specialty boutiques in key markets across the United States. LOH’s key retail concepts include Robert Marc, Optica, Scene, Morgenthal Frederics, Dava
GenMark Diagnostics to Present at Bank of America Merrill Lynch 2015 Health Care Conference
CARLSBAD, Calif.–(BUSINESS WIRE)–GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at th…
Eleven Biotherapeutics Publishes Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Phase 2 Results Published in Eye and Contact Lens Demonstrate Statistically Significant and Clinically Meaningful Improvements with EBI-005 and Support Planned Phase 3 Clinical Study Design
Tyrogenex Initiates the APEX study, a Phase 2 Trial of Oral Treatment with X-82 for Wet AMD
PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, announced the initiation of a phase 2 study referred to as “APEX.”
Aerie Pharmaceuticals to Announce First Quarter 2015 Financial Results and Host Conference Call on Thursday, May 7, 2015
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), announced today that its first quarter 2015 financial results will be released after the market closes on Thursday, May 7, 2015. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business and strategic update. Additionally, the Company
First FDA Cleared Ophthalmic App for Monitoring AMD and DR
DALLAS–(BUSINESS WIRE)–Vital Art and Science, LLC (VAS), an emerging ophthalmic medical device company, has introduced the mVT™ Service, an innovative medical device and physician portal that conveniently and accurately tracks the progression of vision damaging diseases such as age related macular degeneration and diabetic retinopathy. The device is available only by prescription and consists of an easily downloaded app that can be used on any Apple smartphone or tablet. Patient test data are
Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies
BOSTON–(BUSINESS WIRE)–Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for mitochondrial dysfunction, today announced expansion of its ophthalmology program.
New Treatment for Chronic Eye Problems in Midwest
COLUMBUS, Ohio–(BUSINESS WIRE)–The Cataract & Refractive Center of Ohio released an advisory alert to educate people across the Midwest about a new treatment for chronic eye problems suffered by millions of Americans. Those problems are often worse during the spring in the Midwest, when the air is flooded with pollen from maple trees and other plants. In the advisory, Alice T. Epitropoulos, MD, FACS, co-founder of The Eye Center of Columbus, explains that more than 23 million Americans su